May 27 |
7 Biotech Stocks to Put on Your Breakthrough Radar
|
May 24 |
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
|
May 22 |
Party Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings Forecasts
|
May 14 |
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
|
May 13 |
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sen...
|
May 12 |
Cantor picks 14 undervalued biotech stocks worth a second look
|
May 4 |
What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
|
May 3 |
BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
|
May 3 |
BridgeBio Oncology Therapeutics launches with $200m funding
|
May 2 |
BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of $211.12M beats by $127.34M
|